Pipeline

A pipeline innovated by the global human crisis

Indivior is pioneering the development and discovery of non-opioid treatment strategies for OUD, as well as exploring new therapies to potentially address the needs of people suffering from alcohol, stimulant and cannabis use disorders. 

Indivior’s R&D has led to a range of daily and monthly treatment options for patients with moderate-to -severe opioid use disorder. We also developed a monthly treatment option for the treatment of schizophrenia in adult patients. 

Indivior’s quarterly R&D and pipeline update can be found here.

 

Brand Name/Product Candidate

Preclinical

Phase 1

Phase 2

Phase 3

Regulatory Approval

Commercial Launch

 
 
 
 
 
 
 
  •  
    Treatment for Opioid Use Disorder

    Buprenorphine Sublingual Tablet

  •  
    Treatment for Opioid Use Disorder

    Buprenorphine/Naloxone Sublingual Tablet

  •  
    Treatment for Opioid Use Disorder

    Buprenorphine/Naloxone Sublingual Film

  •  
    Treatment for Opioid Use Disorder

    RBP-6000 - Buprenorphine XR injection for Subcutaneous Use

  •  
    Treatment for Schizophrenia

    RBP-70001 - Risperidone XR injection for Subcutaneous Use

  •  
    Treatment for Cannabis Use Disorder

    AEF01172 - Cannabinoid-1 receptor synthetic Signaling Specific inhibitor (SSi)

  •  
    Treatment for Substance Use Disorder

    INDV-20003 - Selective Orexin-1 Receptor Antagonist

  •  
    Treatment for Substance Use Disorder

    INDV-10004 - Gamma-aminobutyric acid subtype B (GABA) positive allosteric modulator (PAM)